Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for chronic liver disease-related thrombocytopenia undergoing elective invasive procedures
CTR20230919Phase 3Completed
- Sponsor
- Shenyang Sansheng Pharmaceutical Co., Ltd.
- Start
- May 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human thrombopoietin in Thrombocytopenia, sponsored by Shenyang Sansheng Pharmaceutical Co., Ltd.. Started May 2023; status: completed.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on CTR20230919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230919.